Macular telangiectasia type 2 (MacTel) is a chronic, progressive, bilateral macular dystrophy that primarily affects individuals in midlife. Characterized by insidious central vision loss and retinal degeneration, it often goes undiagnosed until advanced stages. Recent advancements, such as the approval of revakinagene taroretcel (Encelto), offer new hope for treatment. Early detection and informed patient counseling are crucial to optimizing therapeutic outcomes.
Source: Retinal Physician